AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

30/09 Earnings release - Q2 2026

More about the company

Quarterly revenue - Rate of surprise

Company calendar

Real-time OTC Markets 10:27:29 28/05/2026 pm IST			5-day change	1st Jan Change
1.120 ^USD	-90.26%		-.--%	-22.76%

17/08	AB Science completes settlement and delivery of its private placement
10/08	AB Science Wraps Up EUR14 Million Private Placements	MT

Market Cap	5.55Cr 6.47Cr 5.19Cr 4.75Cr 8.91Cr 619.36Cr 9.03Cr 61Cr 24Cr 311.13Cr 24Cr 24Cr 1.03TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.55Cr 6.47Cr 5.19Cr 4.75Cr 8.91Cr 619.36Cr 9.03Cr 61Cr 24Cr 311.13Cr 24Cr 24Cr 1.03TCr	EV / Sales 2026 *	46.2x	EV / Sales 2027 *	42.7x
Free-Float	69.03%	Yield 2026 *	-	Yield 2027 *	-

17/08	AB Science completes settlement and delivery of its private placement
10/08	AB Science Wraps Up EUR14 Million Private Placements	MT
10/08	AB Science raises €14.2m
13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
10/07	AB Science streamlines its portfolio and refocuses on two molecules
10/07	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
08/07	Stéphane Ledermann takes the helm at AB Science as CEO
07/07	AB Science S.A. Announces Board Changes	CI
07/07	AB Science S.A. Announces CEO Changes	CI
03/07	AB Science S.A. announced that it has received $2.01616 million in funding	CI
01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI
29/06	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI

17/08	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL
10/08	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million	GL
04/08	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
10/07	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
08/07	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU

AB Science Share Price OTC Markets

Stocks

ABSCF

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quarterly revenue - Rate of surprise

08:46pm	AB Science : Franchissement de seuils et déclaration d'intention
17/08	Bourse : Stellantis s'agite, ArgenX communique et PayPal fait monter les enchères
17/08	AB Science procède au règlement-livraison de son placement privé
17/08	AB Science : annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
17/08	AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026

Current year	1.12	1.37
1 year	1.12	1.45
3 years	0	3.84
5 years	0	17.1
10 years	0	26.7

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-90.26%	-.--%	-	-	6.47Cr
MERCK & CO., INC.	-1.29%	+10.26%	+75.73%	+36.97%	38TCr
MERCK KGAA	+0.58%	+1.80%	+26.23%	-13.62%	7TCr
HALOZYME THERAPEUTICS, INC.	-0.76%	+4.38%	+48.89%	+154.52%	1.23TCr
KYOWA KIRIN CO., LTD.	+0.10%	-0.02%	-2.27%	-1.83%	848.57Cr
SK BIOPHARMACEUTICALS CO., LTD.	+3.23%	-1.03%	-12.64%	+1.29%	472.97Cr
YUHAN CORPORATION	+2.43%	+0.72%	-26.70%	+18.02%	442.88Cr
BETTA PHARMACEUTICALS CO., LTD.	-5.18%	-29.35%	-25.38%	+9.87%	320.32Cr
SUPERNUS PHARMACEUTICALS, INC.	-0.61%	-5.53%	+2.63%	+44.03%	266.51Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-3.09%	-6.96%	-16.61%	-6.08%	211.29Cr
Average	-9.47%	+0.63%	+7.76%	+27.02%	5.38TCr
Weighted average by Cap.	-0.99%	+9.90%	+63.25%	+31.11%

	2026 *	2027 *
Net sales	12L 14.01L 11.23L 10.28L 19.29L 13Cr 19.54L 1.33Cr 51.73L 6.73Cr 52.6L 51.46L 22Cr	13L 15.18L 12.16L 11.13L 20.9L 15Cr 21.17L 1.44Cr 56.04L 7.29Cr 56.99L 55.75L 24Cr
Net income	-	-
Net Debt	-	-